This is a fair point, but it's part of a series of video presentations at a number of events where the background to their work has been made clear. Through these films, Dr Davis is trying to keep up the morale of people who've been waiting decades for some good news – and it absolutely is good news, because it's good science. The theory might be completely wrong; but if it is, they'll say so openly and promptly. For people like me, ill for nearly 45 years, that alone is immensely hopeful.
ETA: words 'an' and 'mutation' added for clarity.
Well, I would like to see the nanoneedle test Bravo probiotic. In our case, it helps with neurological pain, mcs, sleep. It is not a definite answer but it provides help. It is the only thing we have stuck with when everything else stopped, including vitamins except vitamin c and magnesium. Don[t take too much when you start. I notice that although it has been around for a few years that people dont talk about it. But my cfs family member does not miss a single day taking it because she goes downhill the next day even.
Since she is particularly sensitive and she is able to take it I think it will agree with most people.
I hope we get some more good news soon!
Finding out the mutation is present in 90% controls is a little bit perturbing, agreed. However, if we phrase it differently and say people without the IDO2 mutation can not get ME/CFS, they’re somehow inherently protected against the possibility of ever contracting it, then you can see why it becomes an intriguing data point. To announce this with any degree of confidence beyond random chance, I’d want a very big data set. I hope they have that.Ron Davis' video linked above offered zero context about how common the IDO2 mutation might be.
Further, he seems to suggest that ALL ME/CFS patients carry the mutation as if this is a significant finding and it is the finding that seems to drive his hypothesis.
Without including a reasonable context for the distribution of this mutation, I find the video irresponsible. IMO it raises false hopes.
Bill
Finding out the mutation is present in 90% controls is a little bit perturbing, agreed. However, if we phrase it differently and say people without the IDO2 mutation can not get ME/CFS, they’re somehow inherently protected against the possibility of ever contracting it, then you can see why it becomes an intriguing data point. To announce this with any degree of confidence beyond random chance, I’d want a very big data set. I hope they have that.
Dr. Phair has said that when he first started looking into ME/CFS he realized the that if a genetic mutation were involved it would have to be relatively common. Why? Because only a common genetic factor could explain the outbreaks where the attack rates could be as high as 25%.
He was also looking for a mutation that could create a "bi-stable" state - i.e. one which alters a stable normal state into an equally stable abnormal state.
No suggestion it could be a biomarker, it obviously couldn't. It's about predisposition.Wow. If it is true that 90% of controls also carry this mutation, it strikes me as irresponsible to throw out the hope that an IDO2 mutation will somehow serve as a marker for ME/CFS.
But presumably that's what science is often about? Once you identify a potential illness mechanism, but with a great many possible causes, there may be no choice but to do the grunt work and keep trying them until you find the right one ... assuming your theory was right in the beginning. It's presumably also possible - maybe even likely? - that as you do this you may turn up a few more clues along the way.The problem is there are hundreds if not thousands of possibilities that fit that criteria.
It's presumably also possible - maybe even likely? - that as you do this you may turn up a few more clues along the way.
How big was the cohort? The small difference between the control group and the patient could be due to the small sample size.
And even if the cohorts are big enough, is the difference (98% patients, 90% control) big enough to tell us anything?
- Helmfrid on Twitter said he thinks they tested at least 70 patients. I am assuming 70 for this calculation. But if it was more than 70, then that would make our p-value even lower.